More recently, inheritance of either homozygous or compound heterozygous biallelic germline MMR gene mutations has been recognized to predispose to a range of childhood cancers, and is now called constitutional mismatch repair deficiency (CMMRD) syndrome. 4 CMMRD syndrome is characterized by the presence of café-au-lait spots and a broad spectrum of early-onset malignancies. Neoplasms are generally divided into four groups: hematologic malignancies, brain tumors, LS-associated tumors and other malignancies. 4 Concerns about the effectiveness and long-term effects of intensive therapy, including alkylators and radiation, in children with CMMRD syndrome have been expressed. 5 Here we describe the first successful allogeneic cord blood transplant (CBT) for relapsed ALL in a child with CMMRD syndrome.
A previously healthy 3-year-old boy with a negative family cancer history presented with a short history of decreased appetite, pallor and bruising. Physical examination revealed bilateral cervical lymphadenopathy and hepatosplenomegaly. Initial investigations included a full blood count showing Hb 5.2 g/dL, white cell count 7.9 × 10 6 /L (30% blasts) and platelets 3 × 10 6 /L. He was diagnosed with standard risk pre-B-cell ALL (bone marrow aspirate contained 94% blasts; CD10, CD20 and CD38 positive with normal karyotype). There was no central nervous system involvement. The patient was treated with multi-agent chemotherapy according to the Australian and New Zealand Children's Cancer Study Group Trial VI. The protocol consisted of a four-drug induction, consolidation phase, one asparaginase-based intensification and maintenance therapy for a total of 2 years (full protocol available on request). He achieved a CR at the end of induction and remained so for over 2 years from the completion of all chemotherapy. Following an asymptomatic bone marrow relapse (pancytopenia), he received further chemotherapy before undergoing an HLA-identical sibling CBT in second CR. Before conditioning for CBT, he had received a total cumulative dose of cyclophosphamide of 3.5 g m/m 2 . CBT conditioning included 120 mg/kg cyclophosphamide, 10 mg/kg thiotepa and fractionated TBI (12 Gy). The thawed CB graft contained 4.5 × 10 7 /kg total nucleated cells and 0.7 × 10 5 /kg CD34+ cells. GvHD prophylaxis consisted of cyclosporine alone. The early post-transplant course was complicated by moderate mucositis and an episode of Gram positive bacteremia. Engraftment was delayed with granulopoietic engraftment established on day +30 and platelet engraftment on day +55. A erythematous facial rash developed 2 months post transplant. A skin biopsy was not diagnostic and autoimmune markers were all negative. The rash responded rapidly to systemic corticosteroids and flared, but eventually resolved during tapering. All immunosuppression was ceased 7 months post transplant. Marrow engraftment analysis utilizing variable number of tandem repeats and cytogenetic analysis showed 100% donor chimerism from day 21 to day 365 post transplant. Long-term monitoring included regular physical examinations, full blood counts and echocardiograms. No adverse events directly attributable to the CBT were noted. He remained in complete hematological remission for 16 years, until his death from a second malignancy.
In the interim follow-up period, one of the boy's younger sisters (fortuitously not the bone marrow donor) was diagnosed with a glioblastoma multiforme (WHO Grade IV) at age 8 years. She underwent a sub-total surgical resection, followed by focal radiation therapy (59.4 Gy) and oral temozolomide (200 mg/m 2 × 5 days monthly) for 12 months. Over the next 3 years, 2 café-au-lait macules and 4100 lentigines developed. She remains alive 8 years after diagnosis. Immunohistochemical analysis (IHC) on the tumor showed a normal pattern of expression of MLH1, MSH2 and MSH6 but complete absence of PMS2 expression. DNA was extracted from peripheral blood lymphocytes of both siblings, and Sanger sequencing of the gene PMS2 identified a missense mutation c.137G4T (p.Ser46Ile). Multiplex ligation-dependent probe amplification) assay of PMS2 detected a second mutation comprising complete deletion of exon 10-c.989?_1144+?del (p.Glu330_Glu381del). Although both mutations have been described in LS, 5 the combination has not previously been documented in over 150 cases of CMMRD. The children's parents were aged 43 and 35 years of age at the time of the first childhood cancer diagnosis. They were not related other than by marriage, both had maintained good health and there was no significant family history of cancer. They underwent genetic testing, which confirmed that each parent harbored a single PMS2 mutation, consistent with diagnoses of LS.
Over time, the index patient developed one café-au-lait macule and multiple lentigines. Following confirmation that he also inherited biallelic compound heterozygosity for PMS2 mutations at age 17 years, the patient underwent colonoscopy and was found to have over 30 colonic polyps, with 1 large polyp suggestive of cancer. He underwent a sub-total colectomy, and histopathological analysis showed adenomatous polyps with low-grade dysplasia. Analysis of the suspicious polyp revealed intramucosal adenocarcinoma, with no submucosal invasion and no evidence of nodal metastases. IHC confirmed the absence of PMS2 staining in both the adenocarcinoma and normal colonic epithelium, consistent with CMMRD syndrome. He died from widely metastatic colonic adenocarcinoma, aged 24 years.
This case is the first to document a successful allogeneic CBT for ALL in a child with CMMRD syndrome. The only previously reported cases of transplantation for leukemia associated with CMMRD syndrome were in a 6-year-old girl with AML who died from medulloblastoma o 12 months later, 6 a 2-year-old girl with AML who relapsed 5 months after transplant and subsequently succumbed to a post-transplant lymphoproliferative disorder 7 and a child of unknown age with AML who died of toxicity related to GvHD. 8 There has also been a single case report of a 7-year survival after HSCT in a 6-year-old girl with a relapsed mediastinal T-cell non-Hodgkin's lymphoma. 9 Our patient with a late relapse ALL certainly had a better long-term prognosis when compared with these four patients, but the factors that determine which patients will develop a second malignancy and when this will occur are still to be determined. Although colorectal carcinoma in adolescence and young adults is well described and one of the hallmarks of CMMRD syndrome, we cannot exclude the possibility that the bone marrow transplant conditioning (particularly the radiation) accelerated its onset in our patient.
At the time of transplant, the patient was not known to carry compound heterozygous PMS2 mutations. It is not uncommon in children with CMMRD syndrome to lack a positive family cancer history. This probably reflects the relatively young adult age of parents and perhaps a milder LS phenotype. In addition, although many CMMRD syndrome patients are identified within families with consanguinity, this is not always the case, especially where compound heterozygous mutations are responsible for the syndrome. Furthermore, a diagnosis of a B-cell ALL in early childhood is a relatively common presentation and, although well described in CMMRD syndrome, is less suggestive of the syndrome's presence than early-onset T-cell ALL/lymphoma. 10 Recently, the European consortium 'care for CMMRD' proposed a three point scoring system for the suspected diagnosis of CMMRD in a pediatric/young adult cancer patient. 11 Tumors highly specific for CMMRD syndrome are assigned three points, malignancies over-represented in CMMRD two points and all other malignancies one point. According to their specificity for CMMRD and their frequency in the general population, additional features are weighted with one to two points. These include multiple hyperpigmented and hypopigmented skin areas, brain malformations, pilomatricomas, a second childhood malignancy, a LS-associated tumor in a relative and parental consanguinity. According to the scoring system, CMMRD should be suspected in any cancer patient who reaches a minimum of three points by adding the points of the malignancy and the additional features. In our case, the selection of a sibling cord donor who had not inherited a MMR gene mutation from either parent was completely fortuitous.
The diagnosis of CMMRD syndrome should be confirmed by gene-specific mutation analysis. Reliable methods for all four MMR genes, including PMS2, are now available. Mutation analysis will facilitate identification and surveillance of compound heterozygote and homozygote individuals in the wider family, allow for informed decision-making about appropriate cancer surveillance, and potentially identify HLA-matched but nevertheless unsuitable sibling donors.
Unlike many patients with impairment of DNA repair mechanisms, our patient did not suffer significant acute or long-term toxicities related to his leukemia, the therapeutic interventions or the CBT. Given appropriate surveillance and where possible early intervention for second malignancies, 5 as seen in our patient and his sibling, long-term survival with excellent quality of life can be expected following transplant. We conclude therefore that allogeneic CBT/bone marrow transplant is a viable therapeutic option in children with ALL associated with CMMRD syndrome.
